Cartalax
Cartalax (Cartilage Bioregulator)
Cartalax is a short-chain tripeptide (Ala-Glu-Asp-Gly) derived from cartilage tissue, developed as part of the Russian peptide bioregulator program by Khavinson and colleagues. It is primarily used to support cartilage regeneration, joint health, and connective tissue repair, with applications in osteoarthritis management and age-related cartilage degradation. Research has focused on its ability to stimulate chondrocyte proliferation and extracellular matrix synthesis in cartilage tissue.
Mechanism of Action
Cartalax functions as a peptide bioregulator that penetrates cell nuclei and interacts with specific DNA promoter regions to upregulate genes associated with chondrocyte function and extracellular matrix production, including collagen type II and proteoglycans. It exhibits epigenetic signaling properties, activating transcription factors that promote anabolic processes in cartilage tissue while reducing pro-inflammatory cytokine expression such as IL-1β and TNF-α. This mechanism mirrors other Khavinson-developed tissue-specific peptides that act as short signaling molecules to restore tissue homeostasis.
Evidence by Health Goal(8 goals)
Dosing Protocols
Morning, preferably on an empty stomach or at least 1 hour before meals
Cycle: 10 days on, then reassess; commonly repeated 2-4 times per year
Subcutaneous injection is most commonly used; reconstitute lyophilized powder in bacteriostatic water. Some protocols use a 10-day course repeated quarterly.
On empty stomach, 30 minutes before first meal
Cycle: 30 days on, 1-3 months off
Oral bioavailability is lower than injection; higher doses are used to compensate for gastrointestinal degradation. Enteric-coated capsule formulations preferred.
Safety & Side Effects
Cartalax has a favorable safety profile based on available preclinical and limited clinical research, with no significant toxicity reported at therapeutic doses. However, human clinical trial data remains limited and largely derives from Russian-language publications; long-term safety in diverse populations has not been rigorously established by large-scale Western regulatory standards.
Possible Side Effects
- !Mild injection site reactions including transient redness or swelling
- !Temporary fatigue or flu-like sensation during initial dosing cycles
- !Rare local edema near treated joints when used with intra-articular protocols
- !Mild gastrointestinal discomfort if taken orally without food
- !Theoretical hypersensitivity reaction in individuals sensitive to peptide-based compounds
Interactions
- -May potentiate the anabolic effects of growth hormone or IGF-1 therapies - monitor for excess tissue growth
- -Potential additive benefit when combined with glucosamine or chondroitin sulfate supplementation
- -May enhance anti-inflammatory effects of NSAIDs - combined use could theoretically reduce NSAID dose requirements
- -Use caution with immunosuppressive therapy as peptide bioregulators may modulate immune-adjacent cellular signaling
- -May interact synergistically with other Khavinson peptides (e.g., Sigumir, Chonluten) - combined protocols not well studied
Cost & Where to Buy
Cost varies significantly by source and formulation; Russian-manufactured products (e.g., Cytomax/Peptide Bioregulator lines) tend to be more affordable, while research-grade Western peptide vendor sources are typically higher. Lyophilized injectable powder is generally more expensive than oral capsule forms.
Search on Amazon